Table 4.
Clinical characteristics of patients included in the retrospective analysis of the relationship between time to remission and cumulative dose of rituximab required to achieve remission as function of machine learning algorithm prediction
| Variables | Patients (N = 45) |
|---|---|
| Characteristics at rituximab infusion | |
| Age (yrs) | 56 (42–67) |
| Gender (male/female) | 30/15 |
| Weight (kg) | 74.0 (66.0–87.3) |
| Height (cm) | 172 (165–178) |
| Body mass index (kg/m2) | 26 (23–28) |
| Serum albumin (g/l) | 22.1 (16.0–27.8) |
| Urinary protein-to-creatinine ratio (g/g) | 5.6 (4.1–8.7) |
| Serum creatinine (μmol/l) | 117 (88–169) |
| Glomerular Filtration Rate estimated by CKD-EPI formula (ml/min per 1.73 m2) | 54 (36–82) |
| Etiology | |
| Anti-PLA2R1-associated membranous nephropathy | 41 (91%) |
| Anti-THSD7A-associated membranous nephropathy | 1 (2%) |
| Antigen responsible not identified | 3 (7%) |
| Anti-PLA2R1 titer (RU/ml) | 153 (62–255) |
| Rituximab protocol | |
| 375 mg/m2 D0–D8 | 3 (7%) |
| 1000 mg D0–D15 | 42 (93%) |
| Supportive therapy | 45 (100%) |
| Serum rituximab level at month-3 | |
| <2 μg/ml | 27 (60%) |
| >2 μg/ml | 18 (40%) |
| CD19+ cell count | |
| CD19+ cell count at month-3 (cells/μl) | 2 (0–5) |
| CD19+ cell count at month-6 (cells/μl) | 28 (6–56) |
| Outcome | |
| Remission at month-6 | 24 (53%) |
| Remission at month-12 | 36 (80%) |
| Remission at month-24 | 40 (89%) |
| End stage kidney disease at month-24 | 4 (9%) |
| Cumulative rituximab dose | 2 (2–4) |
| Time to remission (mos) | 6 (3–11) |
CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; D0: day-0; D8: day-8; D15: day-15; PLA2R1: phospholipase A2 receptor type 1, THSD7A: Thrombospondin Type 1 Domain Containing 7A